LDS/Medical Tests/FibroTest (FibroSURE), Liver Fibrosis Test

FibroTest (FibroSURE), Liver Fibrosis Test

Although the incidence of hepatitis C infection has decreased in the past two decades, the infection is prevalent in 3.2 million people in the United States and 3% of the population worldwide. Only a small percentage of individuals with hepatitis C infection clear the virus and the rest (75-80%) develop chronic hepatitis. According to WHO, there are more than 170 million people worldwide affected by chronic hepatitis C and are at risk of developing cirrhosis of the liver and hepatocellular carcinoma. Determining the disease activity and progression to fibrosis of the liver is a key factor in the management of chronic hepatitis C infection.

Histologic examination of the liver biopsy is considered the gold standard to assess the degree of hepatic injury. The Metavir scoring system, a standardized histopathologic system to grade the fibrosis, guides subsequent clinical management of the patient. However, liver biopsy is expensive, invasive, and carries a risk for few but potentially serious complications including hemorrhage and pneumothorax. Recently, noninvasive techniques have been developed and validated to assess the degree of fibrosis.

HCV FibroSURE is a noninvasive blood test that utilizes a panel of six biochemical markers together with the patient’s age and gender to generate a score using a proprietary algorithm to guide clinical decisions. The markers include α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, γ-glutamyl transpeptidase (GGT), and ALT. The calculated score determines the degree of fibrosis and inflammatory pattern of liver injury. The algorithm has been extensively validated to assess the pattern of liver injury in viral hepatitis and other chronic liver diseases. HCV FibroSURE is a cost-effective diagnostic tool and minimizes the need for invasive liver biopsies by providing scores that show linear correlation with the Metavir scoring system.

  • To assess the degree of fibrosis and necroinflammatory activity in chronic hepatitis C infection
  • To determine the baseline status of chronic hepatitis C infection before initiation of therapy
  • To evaluate for fibrosis in other liver inflammatory diseases including hepatitis B, autoimmune hepatitis, liver hepatitis, alcoholic cirrhosis, fatty liver disease and Acquired immunodeficiency syndrome
  • To monitor treatment and disease management

HCV FibroSURE scores are reported as FibroTest and ActiTest scores.

FibroTest scores correlate with the degree of fibrosis and help in staging the disease.

ActiTest scores correlate with the degree of inflammation and help grade the hepatocellular injury.

The FibroTest and ActiTest scores are increased in: Chronic hepatitis C infection with progression to cirrhosis

FibroTest score: <0.21

ActiTest score: <0.17

 

Reference Interval in more details

α2-macroglobulin: 110-276 mg/dL

Haptoglobin: 34-200 mg/dL

Apolipoprotein A1: 110-205 mg/dL (female)

                           110-180 mg/dL (male)

Bilirubin, total: 0.1-1.2 mg/dL

γ-glutamyl transpeptidase (GGT): 0-65 IU/L

Alanine aminotransferase (ALT): 0-40 IU/L (female)

                                               0-55 IU/L (male)

Metavir Scoring System

Fibrosis Stage (FibroTest)

F0 - No fibrosis < 0.21

F0 - F1 0.21 - 0.27

F1 - Portal fibrosis 0.27 - 0.31

F1 - F2 0.31 - 0.48

F2 - Bridging fibrosis with few septa 0.48 - 0.58

F3 - Bridging fibrosis with many septa 0.58 - 0.72

F3 - F4 0.72 - 0.74

F4 - Cirrhosis > 0.74

 

Activity Grade (ActiTest)

A0 - No activity < 0.17

A0 - A1 0.17 - 0.29

A1 - Minimal activity 0.29 - 0.36

A1 - A2 0.36 - 0.52

A2 - Moderate activity 0.52 - 0.60

A2 - A3 0.60 - 0.62

A3 - Severe activity > 0.62

A proprietary algorithm is used to obtain FibroTest and ActiTest scores using a panel of six serum markers, viz. α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, γ-glutamyl transpeptidase (GGT), and ALT, together with the patient’s age and gender.

Serum (minimum 3mL)

Collect 10 cc of blood through venipuncture in a red-stopper tube or gel-barrier tube, separate serum from cells within one hour of collection and refrigerate at 2°C to 8°C.

Stability

  • Refrigerated: 72 hours
  • Frozen: More than a month
  • Protect from light.
Correlation with liver biopsy may be required if clinically indicated, other liver enzymes, Liver profile, Hepatitis C viral load and genotyping, Hepatitis C serology.
2-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login